Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials

Grill, Joshua D; Karlawish, Jason

doi:10.1186/alzrt58

Alzheimer's Research & Therapy

Table 3 Retention rates from a sample of Phase II and Phase III Alzheimer's disease clinical trials

From: Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials

	Treatment under study	Study enrollment	Active completers	Placebo completers	Trial length, months
Mild cognitive impairment	Rofecoxib [54]	1,457	687/725 = 0.95	702/732 = 0.96	48
	TRIMCI study of trifusal [7]	257	104/129 = 0.81	119/128 = 0.93	18
	Donepezil [57]	270	90/133 = 0.68	114/137 = 0.83	6
	Vitamin E and donepezil [38]	790	346/510 = 0.68	193/259 = 0.74	36
	Rivastigmine [55]	1,018	312/508 = 0.61	346/510 = 0.68	48
	Donepezil [58]	821	226/409 = 0.55	273/412 = 0.66	12
	Two studies of galantamine [56]	2,057	476/1,029 = 0.46	543/1,028 = 0.53	24
Mild-to-moderate AD	Dimebon [59]	183	78/89 = 0.88	77/94 = 0.82	4
	Gamma secretase inhibitor [62]	51	32/36 = 0.89	12/15 = 0.80	4
	Rosiglitazone [65]	518	106/122 = 0.87	336/389 = 0.86	6
	High-dose B vitamin [66]	409	204/240 = 0.85	140/169 = 0.83	18
	Rivastigmine patch [63, 64]	1,195	704/893 = 0.79	266/302 = 0.88	6
	Estrogen replacement [6]	120	65/81 = 0.80	32/39 = 0.82	15
	Galantamine [69]	978	539/692 = 0.78	240/286 = 0.84	5
	Rofecoxib [37]	351	179/240 = 0.74	88/111 = 0.79	12
	DHA (Joseph Quinn, personal communication)	402	178/241 = 0.74	129/161 = 0.80	18
	Bapineuzumab [10]	234	92/122 = 0.75	87/107 = 0.81	18
	AN1792 [61]	372	223/299 = 0.74	53/73 = 0.73	12
	Idebenone [60]	536	281/407 = 0.69	96/129 = 0.74	12
	Atorvastatin [39]	640	207/314 = 0.66	245/326 = 0.75	18
	Galantamine [70]	636	266/423 = 0.63	172/213 = 0.81	6
	Tarenfl urbil [9]	1,684	506/862 = 0.59	540/822 = 0.66	18
Moderate-to-severe/Severe AD	Selegeline/Alpha tocopherol [71] CDR 2	341	240/257 = 0.93	78/84 = 0.93	24
	Donepezil [72] MMSE 5 to 17	291	121/144 = 0.84	126/146 = 0.86	6
	Donepezil [5] MMSE 1 to 10	249	95/128 = 0.74	99/120 = 0.82	6
	Memantine [67] MMSE 5 to 14	350	134/178 = 0.75	126/172 = 0.73	6
	Memantine [12] MMSE 3 to 14	252	97/126 = 0.77	84/126 = 0.67	7
	Donepezil [68] MMSE 1 to 12	343	117/176 = 0.66	127/167 = 0.76	6
	Memantine [13] MMSE 5 to 14	404	172/203 = 0.85	150/201 = 0.75	6

AD, Alzheimer's disease; CDR, Clinical Dementia Rating; DHA, docosahexaenoic acid; MMSE, Mini-Mental State Examination.

Back to article page

ISSN: 1758-9193

Contact us

General enquiries: journalsubmissions@springernature.com